Catcher Technology (2474) Q4 2025 earnings summary

Executive summary

• 4Q25 revenue was NT$4.363bn, down 10.2% quarter-over-quarter and 5.9% year-over-year, impacted by electronics component shortages and customer inventory adjustments, partially offset by medtech growth.

• Consolidated financial statements audited and found to present fairly the financial position as of December 31, 2025 and 2024, in accordance with IFRS and local regulations.

• Net profit after tax for 4Q25 was NT$2.378bn, down 17.5% q-o-q and 36.7% y-o-y; full-year 2025 NPAT was NT$7.147bn, down 49.5% y-o-y.

• Pacific Hospital Supply Co., Ltd. was acquired and consolidated as a subsidiary from January 2025.

• Significant treasury share buybacks and capital reductions occurred throughout 2025.

Financial highlights

• 2025 revenue grew 3.2% y-o-y to NT$18,658,836 thousand, driven by medtech contributions.

• Net profit for 2025 was NT$7,332,587 thousand, down 44% from NT$13,199,016 thousand in 2024.

• Basic EPS for 2025 was NT$11.33, compared to NT$19.40 in 2024.

• Total comprehensive income for 2025 was NT$2,636,724 thousand, a significant decrease from NT$16,801,780 thousand in 2024, mainly due to large foreign currency translation losses.

• Cash and cash equivalents at year-end 2025 were NT$43,747,619 thousand, down from NT$50,364,287 thousand at year-end 2024.

Outlook and guidance

• Ongoing diversification into medtech, semiconductor, and aerospace sectors, with significant investments planned over 5–10 years.

• Overseas expansion includes new facilities in Thailand and Vietnam, with production ramp-up scheduled for 2026–2027.

• Strategic focus on R&D, global production capacity, and M&A to drive long-term growth.

• Management continues to focus on stable dividend growth and capital allocation for expansion.

• IFRS 18 and other new standards are being assessed for future impact, with no material effect expected in the near term.